Research Analysts Set Expectations for YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABFree Report) – Equities researchers at Cantor Fitzgerald increased their FY2024 EPS estimates for shares of Y-mAbs Therapeutics in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.66) per share for the year, up from their previous forecast of ($0.67). Cantor Fitzgerald currently has a “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the previous year, the firm posted ($0.18) earnings per share.

Several other research analysts have also recently weighed in on YMAB. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, BMO Capital Markets decreased their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

View Our Latest Report on YMAB

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $13.18 on Thursday. The business has a 50 day simple moving average of $14.08 and a 200 day simple moving average of $13.13. Y-mAbs Therapeutics has a 52-week low of $5.04 and a 52-week high of $20.90.

Insider Transactions at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock worth $1,338,100 in the last 90 days. Corporate insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Ameritas Investment Partners Inc. boosted its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares during the last quarter. Caxton Associates LP acquired a new position in Y-mAbs Therapeutics in the 1st quarter worth about $306,000. Boston Partners bought a new position in Y-mAbs Therapeutics in the first quarter valued at about $556,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

See Also

Earnings History and Estimates for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.